MA42233B1 - DROSPIRENONE-BASED CONTRACEPTIVE FOR AN OVERWEIGHT FEMALE PATIENT - Google Patents

DROSPIRENONE-BASED CONTRACEPTIVE FOR AN OVERWEIGHT FEMALE PATIENT

Info

Publication number
MA42233B1
MA42233B1 MA42233A MA42233A MA42233B1 MA 42233 B1 MA42233 B1 MA 42233B1 MA 42233 A MA42233 A MA 42233A MA 42233 A MA42233 A MA 42233A MA 42233 B1 MA42233 B1 MA 42233B1
Authority
MA
Morocco
Prior art keywords
drospirenone
female patient
contraceptive
based contraceptive
overweight female
Prior art date
Application number
MA42233A
Other languages
French (fr)
Other versions
MA42233A (en
Inventor
Dominique Drouin
Cécile Boyer-Joubert
Philippe Perrin
Original Assignee
Laboratorios Leon Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Leon Farma Sa filed Critical Laboratorios Leon Farma Sa
Priority claimed from PCT/EP2016/064574 external-priority patent/WO2016207298A1/en
Publication of MA42233A publication Critical patent/MA42233A/en
Publication of MA42233B1 publication Critical patent/MA42233B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Abstract

Selon l'invention, de la drospirénone est utilisée en tant qu'agent contraceptif unique compris dans une unité de dosage actif quotidienne, dans une quantité d'au moins 3 mg. La drospirénone est destinée à être utilisée en tant que contraceptif pour une patiente atteinte d'obésité.According to the invention, drospirenone is used as a single contraceptive agent included in a daily active dosage unit, in an amount of at least 3 mg. Drospirenone is intended for use as a contraceptive for a patient with obesity.

MA42233A 2015-06-23 2016-06-23 DROSPIRENONE-BASED CONTRACEPTIVE FOR AN OVERWEIGHT FEMALE PATIENT MA42233B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510348953.1A CN106265694A (en) 2015-06-23 2015-06-23 Contraceptive based on drospirenone for overweight female patient
PCT/EP2016/064574 WO2016207298A1 (en) 2015-06-23 2016-06-23 Drospirenone-based contraceptive for a female patient affected with excess weight

Publications (2)

Publication Number Publication Date
MA42233A MA42233A (en) 2018-05-02
MA42233B1 true MA42233B1 (en) 2024-01-31

Family

ID=57650243

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42233A MA42233B1 (en) 2015-06-23 2016-06-23 DROSPIRENONE-BASED CONTRACEPTIVE FOR AN OVERWEIGHT FEMALE PATIENT

Country Status (2)

Country Link
CN (1) CN106265694A (en)
MA (1) MA42233B1 (en)

Also Published As

Publication number Publication date
MA42233A (en) 2018-05-02
CN106265694A (en) 2017-01-04

Similar Documents

Publication Publication Date Title
MA45598B1 (en) 24-hydroxy steroles substituted in position 11 for the treatment of diseases linked to the nmda receptor
MA40111A1 (en) Derivatives of tetrahydronaphthalene inhibiting mcl-1 protein
MA40290A1 (en) Immune-regulating agents
MA33220B1 (en) Pharmaceutical composition of anti-inflammatory
EA201792595A1 (en) CONTRACEPTIVE MEANS BASED ON DROSPYRENON FOR A PATIENT SUFFERING AN EXCESSIVE BODY MASS
MA38576A1 (en) Colchicine extended-release formulations and methods of using the same
AR060880A1 (en) USE OF FLIBANSERINE FOR THE TREATMENT OF SEXUAL DESIRE POSMENOPAUSIC DISORDERS
MA40768A (en) MONO OR DI-SUBSTITUTE INDOLE DERIVATIVES AS DENGUE VIRUS REPLICATION INHIBITORS
MA47356A1 (en) Isochromene derivatives useful as inhibitors of phosphoinositide 3-kinases
MA41238A (en) DERIVATIVES 5 - [(PIPERAZIN-1-YL) -3-OXO-PROPYL] -IMIDAZOLIDINE-2,4-DIONE AS ADAMT INHIBITORS FOR THE TREATMENT OF OSTEOARTHRIT
FR3058059B1 (en) PHARMACEUTICAL COMPOSITION COMPRISING BETA-ELEMENE, LUPEOL AND 2-HYDROXYCINNAMALDEHYDE AND / OR 2'-BENZOYLOXYCINNALMALDEHYDE AND / OR BETA-SITOSTEROL AND / OR CURCUMIN.
MA37317B1 (en) Antibody formulation il-17
MA43913A (en) POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC M1 RECEPTOR
AU2019210703B2 (en) Cannabinoid dosing regime for dermatitis and inflammatory skin conditions
MA38679A1 (en) Cxcr7 receiver modulators
ZA202006377B (en) Boronic acid derivatives and therapeutic uses thereof
MA39447B1 (en) Pirlindole or its pharmaceutically acceptable salts for use in medicine
MA42769B1 (en) Fluoroindole derivatives as positive allosteric modulators of the m1 muscarinic receptor
MA42233B1 (en) DROSPIRENONE-BASED CONTRACEPTIVE FOR AN OVERWEIGHT FEMALE PATIENT
MA39448B1 (en) (r) -pirlindole and its pharmaceutically acceptable salts for medical use
GT200800235A (en) FORMULATION OF LIQUID MEDICINAL PRODUCT
BR112016026422A2 (en) pharmaceutical solution comprising dopamine for use in the treatment of parkinson's disease
MA42367B1 (en) Pharmaceutical formulation for the treatment of inflammatory rectal changes
MA40179B1 (en) Combination of adapalene and benzoyl peroxide for the treatment of severe acne
MX2015013911A (en) Synergistic combination of paracetamol/celecoxib for the treatment of inflammatory pain.